Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268918 · ClinicalTrials.gov registry record · Phase 1
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT00268918 is a Phase 1 study of Breast Cancer and Ovarian Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00268918, a Phase 1 study of Breast Cancer and Ovarian Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG PTK787
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268918
The ClinicalTrials.gov registry entry for NCT00268918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00268918 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00268918 about?
NCT00268918 is a clinical study titled "Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients". The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.
What is the current status of trial NCT00268918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-09. Estimated completion is 2011-01.
What conditions does trial NCT00268918 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer.
What interventions are being tested in trial NCT00268918?
The interventions under investigation include: Docetaxel (DRUG), PTK787 (DRUG).
Who is sponsoring clinical trial NCT00268918?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00268918 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.